MA53626B1 - Procédés non hormonaux de contraception masculine avec (r)-silodosin - Google Patents
Procédés non hormonaux de contraception masculine avec (r)-silodosinInfo
- Publication number
- MA53626B1 MA53626B1 MA53626A MA53626A MA53626B1 MA 53626 B1 MA53626 B1 MA 53626B1 MA 53626 A MA53626 A MA 53626A MA 53626 A MA53626 A MA 53626A MA 53626 B1 MA53626 B1 MA 53626B1
- Authority
- MA
- Morocco
- Prior art keywords
- contraception
- composition
- present
- silodosin
- male contraception
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862763129P | 2018-03-23 | 2018-03-23 | |
| EP18305328 | 2018-03-23 | ||
| EP20182691.4A EP3750538B1 (en) | 2018-03-23 | 2019-03-22 | Non-hormonal methods for male contraception comprising (r)-silodosin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53626A MA53626A (fr) | 2022-03-09 |
| MA53626B1 true MA53626B1 (fr) | 2024-09-30 |
Family
ID=65955198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53626A MA53626B1 (fr) | 2018-03-23 | 2019-03-22 | Procédés non hormonaux de contraception masculine avec (r)-silodosin |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10912762B2 (https=) |
| EP (2) | EP3562485B8 (https=) |
| JP (1) | JP7270901B2 (https=) |
| KR (1) | KR102496504B1 (https=) |
| CN (1) | CN112074269A (https=) |
| AU (1) | AU2019237228B2 (https=) |
| BR (1) | BR112020018925A2 (https=) |
| CA (1) | CA3094016C (https=) |
| DK (2) | DK3750538T3 (https=) |
| ES (2) | ES2989170T3 (https=) |
| FI (1) | FI3750538T3 (https=) |
| IL (1) | IL277372B2 (https=) |
| MA (1) | MA53626B1 (https=) |
| MX (1) | MX2020009937A (https=) |
| PL (2) | PL3750538T3 (https=) |
| PT (1) | PT3562485T (https=) |
| SG (1) | SG11202008794TA (https=) |
| UA (1) | UA128502C2 (https=) |
| WO (1) | WO2019180217A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3750538T3 (pl) * | 2018-03-23 | 2024-11-25 | Pharmajor International | Niehormonalne sposoby męskiej antykoncepcji obejmujące (r) -sylodosynę |
| AU2023384256A1 (en) * | 2022-11-23 | 2025-03-20 | Pharmajor Incorporated | Modified-release silodosin compositions and use thereof in methods for male contraception |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1091276A (en) | 1911-12-09 | 1914-03-24 | Basf Ag | Producing unsaturated terpene hydrocarbons. |
| US4210644A (en) | 1978-02-23 | 1980-07-01 | The Johns Hopkins University | Male contraception |
| DE4308406C1 (de) | 1993-03-12 | 1994-06-16 | Jenapharm Gmbh | Kombinationspräparat zur Kontrazeption |
| HUP0300128A3 (en) | 2000-02-15 | 2004-03-29 | Schering Ag | Male contraceptive composition comprising norethisterone and its use |
| FR2861990B1 (fr) * | 2003-11-10 | 2006-02-10 | Nouveaux Produits Pharma | Comprimes faiblement doses a reseau de polymeres |
| US20090186896A1 (en) * | 2005-09-29 | 2009-07-23 | Bayer Healthcare Ag | PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders |
| CN101316934A (zh) * | 2005-09-29 | 2008-12-03 | 拜耳医药保健股份公司 | 用于治疗泌尿系统疾病的pde抑制剂及其组合 |
| MX2009003737A (es) * | 2006-10-05 | 2009-06-16 | Panacea Biotec Ltd | Composicion inyectable en deposito y su procedimiento de preparacion. |
| GB0700893D0 (en) | 2007-01-17 | 2007-02-21 | King S College London | Male contraceptive |
| US20080242717A1 (en) | 2007-02-28 | 2008-10-02 | Fumiyasu Sato | Methods for treating benign prostatic hyperplasia |
| US20120184591A1 (en) * | 2011-01-13 | 2012-07-19 | Watson Pharmaceuticals, Inc. | Methods for treating prostatitis |
| CN102283816B (zh) | 2011-08-05 | 2013-09-11 | 北京海步国际医药科技发展有限公司 | 西洛多辛缓释片剂及其制备方法 |
| WO2014118606A2 (en) * | 2013-01-29 | 2014-08-07 | Alembic Pharmaceuticals Limited | A novel process for the preparation of silodosin |
| JPWO2016051782A1 (ja) | 2014-09-30 | 2017-07-13 | キッセイ薬品工業株式会社 | 苦味を有する薬剤の苦味をマスキングした経口投与製剤 |
| US20170049834A1 (en) * | 2015-08-18 | 2017-02-23 | Golden Biotechnology Corporation | Benign prostatic hyperplasia add-on therapy |
| PL3750538T3 (pl) * | 2018-03-23 | 2024-11-25 | Pharmajor International | Niehormonalne sposoby męskiej antykoncepcji obejmujące (r) -sylodosynę |
-
2019
- 2019-03-22 PL PL20182691.4T patent/PL3750538T3/pl unknown
- 2019-03-22 UA UAA202006637A patent/UA128502C2/uk unknown
- 2019-03-22 SG SG11202008794TA patent/SG11202008794TA/en unknown
- 2019-03-22 PT PT197141500T patent/PT3562485T/pt unknown
- 2019-03-22 FI FIEP20182691.4T patent/FI3750538T3/fi active
- 2019-03-22 CA CA3094016A patent/CA3094016C/en active Active
- 2019-03-22 JP JP2021500350A patent/JP7270901B2/ja active Active
- 2019-03-22 WO PCT/EP2019/057267 patent/WO2019180217A1/en not_active Ceased
- 2019-03-22 MA MA53626A patent/MA53626B1/fr unknown
- 2019-03-22 EP EP19714150.0A patent/EP3562485B8/en active Active
- 2019-03-22 ES ES20182691T patent/ES2989170T3/es active Active
- 2019-03-22 DK DK20182691.4T patent/DK3750538T3/da active
- 2019-03-22 AU AU2019237228A patent/AU2019237228B2/en active Active
- 2019-03-22 MX MX2020009937A patent/MX2020009937A/es unknown
- 2019-03-22 KR KR1020207029031A patent/KR102496504B1/ko active Active
- 2019-03-22 ES ES19714150T patent/ES2813084T3/es active Active
- 2019-03-22 CN CN201980030077.4A patent/CN112074269A/zh active Pending
- 2019-03-22 US US16/362,081 patent/US10912762B2/en active Active
- 2019-03-22 DK DK19714150.0T patent/DK3562485T3/da active
- 2019-03-22 BR BR112020018925-1A patent/BR112020018925A2/pt unknown
- 2019-03-22 IL IL277372A patent/IL277372B2/en unknown
- 2019-03-22 PL PL19714150T patent/PL3562485T3/pl unknown
- 2019-03-22 EP EP20182691.4A patent/EP3750538B1/en active Active
-
2020
- 2020-12-30 US US17/137,747 patent/US11583518B2/en active Active
-
2023
- 2023-01-06 US US18/093,940 patent/US11951095B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA48051B1 (fr) | Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide | |
| World Health Organization | WHO model prescribing information: drugs used in leprosy | |
| MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
| EA200801826A1 (ru) | Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения | |
| WO2003105800A3 (de) | Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen | |
| MA46665B1 (fr) | Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y | |
| MA69295B1 (fr) | Dose de départ de conjugués de pth | |
| MA53626B1 (fr) | Procédés non hormonaux de contraception masculine avec (r)-silodosin | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA43817B1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
| MA38694B1 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
| MA56288A1 (fr) | Formes cristallines à l'état solide d'un modulateur sélectif du canal potassique | |
| HRP20241584T1 (hr) | Postupci liječenja sjögrenovog sindroma inhibitorom brutonove tirozin kinaze | |
| Schiavo et al. | Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies | |
| MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| WO2018224736A3 (en) | THERAPEUTICALLY ACTIVE STEROID DERIVATIVES | |
| HRP20231229T1 (hr) | Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje | |
| Fenier et al. | Enalapril improved renal function and proteinuria in chronic glomerulopathies | |
| Norton | The effects of drugs on barbiturate withdrawal convulsions in the rat | |
| MA42769B1 (fr) | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
| Shapiro et al. | Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis | |
| FR2399841A1 (fr) | Combinaison medicamenteuse antithrombotique et procede pour sa preparation | |
| MA47027B1 (fr) | Compositions et procédés non hormonaux pour la contraception masculine avec (r)-silodosin | |
| Chalal et al. | Profil épidémiologique des fibromes utérins dans la région de Sidi Bel Abbes, Algérie |